Archived: Chemicals Management Plan implementation table at a glance - 2016 to 2021
Notice to reader
This is an archived version. Please refer to the current CMP implementation table.
| Regulatory Regime | Planned Government Action | Number of Substances | Rationale for Action | Timelines |
|---|---|---|---|---|
| Canadian Environmental Protection Act, 1999 (CEPA 1999) | Phase 1 and 2 Substances: Complete draft screening assessments of remaining CMP Phase 1 (Challenge Initiative and the Petroleum Sector Stream Approach) and CMP Phase 2 (Groupings Initiative) substances and, as needed, follow-up information gathering or risk management actions. |
Approximately 120 | These substances were identified as priorities under the CMP to be assessed by 2021. The assessments were initiated under phase 1 or 2 of the CMP. | Publication will occur in the early onset of phase 3 of the CMP. For those substances identified for follow-up information gathering actions, measures will be proposed after the final assessment is published. |
| Phase 3 Substances: Conduct risk assessments of remaining priorities, and, as needed, follow-up information gathering or risk management actions. |
Approximately 1,550 List of Substances in the next phase of CMP (2016-2021) |
These substances were identified as priorities under the CMP Plan to be assessed by 2021, or via the review process for the Identification of Risk Assessment Priorities: Results of the 2015 Review. | Assessments will be published as indicated in the two-year rolling risk assessment publication plan. For those substances identified for follow-up information gathering actions, measures will be proposed after the final assessment is published. |
|
| Risk Management (RM) of Toxic Substances: Continuing administration and implementation of over 180 RM instruments and continued development of new instruments. |
Over 600 individual substances represented by 132 listings on Schedule 1 of the CEPA 1999 (List of Toxic Substances) | RM actions, including instruments respecting preventive or control actions (per section 92 of CEPA 1999), are applied to substances concluded as toxic, within the meaning of section 64 of CEPA 1999. Consultation on RM begins when substances are first proposed to be concluded as toxic, and continues throughout the risk management cycle. |
RM actions for toxic substances are to be taken within 3.5 years of the final assessment and statement that the Minister's propose that the substance be added to Schedule 1 of CEPA 1999. RM activities and engagement opportunities will occur on an ongoing basis throughout the RM cycle, and anticipated timelines are provided in the two year rolling risk management activities and consultations schedule. |
|
| Performance measurement: Implement substance based performance measurement (SBPM) for four pilot substances. Develop SBPM plans for additional toxic substances. Conduct effectiveness evaluation for certain CEPA instruments. |
4 plans developed to date Additional substances to be announced |
Performance measurement is used to assess ongoing relevance, success and effectiveness of the actions taken to address the risk, that is, have objectives been met? Substance-based performance measurement is an initiative that considers performance of all instruments, together with relevant data or indicators of exposure to the environment or human health to measure whether environmental and/or human health objectives are being met. |
Ongoing: Information on performance measurement activities is provided in the two year rolling risk management activities and consultations schedule. | |
| Information Gathering Activities: Information gathering activities building on the information submitted by stakeholders via the Domestic Substances List (DSL) Inventory Update in 2012. Access to information via information sharing agreements with domestic and international programs. |
Approximately 1,550 | Updated information on substances in commerce in Canada, volumes and uses is required to support timely risk assessment and risk management decisions. | Information is to be gathered prior to the start of assessment in most cases. Further targeted information gathering may occur after the start of assessment. Information may be gathered to inform risk management actions as required. |
|
| Inventory Update: Inventory Update (IU) on existing substances to determine commercial status |
Approximately 1,500 (TBC after stakeholder consultation) | Updated information on substances in commerce in Canada, volumes and uses is required to inform risk assessment and risk management decisions. | Survey launch planned for 2016 and cyclical every 4 years. | |
| New Substances: Assessment of new substances |
Approximately 500 notifications assessed per year; 30 control measures developed per year. | New Substance Notifications are required for all new substances proposed for introduction into the Canadian marketplace as per the New Substances Notification Regulations under CEPA 1999. | Ongoing. | |
| Products of Biotechnology: Publication of draft and final screening assessments of micro-organisms on the DSL that were assessed during the second phase of the CMP. |
Approximately 16 draft and 21 final publications. | 68 organisms were identified for assessment under section 74 of CEPA 1999, and assessed during CMP Phase 2. | Publication of all final assessments by 2017-18. | |
| DSL Nanomaterials: Prioritisation of substances in commerce according to responses to the section 71 survey. Screening assessment of high priority nanomaterials on the DSL. |
TBD (dependent on results of information gathering initiatives, currently underway) | Prioritization is needed to identify which substances should be assessed for risks to the environment or human health. | Develop and implement Government of Canada approach and guidance for the prioritization of existing nanomaterials, complete prioritisation by 2018. Assessments completed and published as required. |
|
| Monitoring: Ongoing monitoring of chemicals in the environment and humans. |
Varies by monitoring activities and program needs; up to 90 substances measured in human biomonitoring studies. | Monitoring provides essential information used to make sound and effective public health and environmental health policies and interventions, and helps to measure the effectiveness of Government actions to limit or reduce potential risks to humans and/or the environment. | Various ongoing initiatives, including reports on Cycle 4 of the Canadian Health Measures Survey (CHMS) in 2017 and Cycle 5 in 2019, and annual review of environmental monitoring activities based on program priorities. | |
| Research: Research on effects, exposure and methods and tool development. |
Varies by project and program needs. | Research is needed to better understand the exposure and effects of a variety of chemicals that were identified as priorities under the CMP, as well as to develop new tools to efficiently and effectively assess risks. | Complete 3rd cycle of research projects by March 2017 and launch 4th cycle of research projects in 2017-18. Environmental research projects to be conducted from 2016 to 2019. Launch of next cycle of environmental research projects in 2019-2020. |
|
| Compliance and Enforcement | Depending on number of assessed and the resultant risk management outcomes. | Compliance promotion and enforcement activities ensure that regulatees are aware, understand and comply with regulatory requirements. | Ongoing. | |
| Drinking Water: Guidelines for Canadian Drinking Water Quality. |
Approximately 5 per year (new or revised). | These health-based guidelines for existing, new and emerging contaminants that can impact health are developed through a Federal-Provincial-Territorial process. They are used by all jurisdictions in Canada to establish drinking water requirements to protect public health. | Ongoing. | |
| Canada Consumer Product Safety Act (CCPSA) Cosmetic Regulations under the Food and Drugs Act (F&DA) |
Consumer Products and Cosmetics: Continued surveillance of consumer products and cosmetics through analytical testing of levels of substances in these products. |
Levels of substances in these products currently on the market are required to inform risk assessment, and to target appropriate risk management actions. | Ongoing. | |
| Pest Control Products Act (PCPA) | Pesticides: Initiate re-evaluations Re-evaluation of registered pesticides. |
As required. | The PCPA requires a cyclical review (15 years) of all pesticides. | 2016 to 2021, or according to PCPA timelines. |
| Pesticides: re-evaluation of older chemicals. |
46 older active ingredients in 1,817 substances. | The PCPA requires that all pesticides registered prior to 1995 be re-evaluated. | 2016 to 2021, or according to PMRA published work plan. | |
| Pesticides: Initiate special reviews (see Regulatory Directive: Pest Management Regulatory Agency Re-evaluation Program - program 4). |
As required. | Special reviews will be undertaken where there are reasonable grounds that health and environmental risks or value of a pesticide is unacceptable or when a member country of the Organization for Economic Co-operation and Development prohibits all uses of an active ingredient for health or environmental reasons. | Action as required. | |
| Pesticides: Continue to monitor pesticide health and environmental incidents and take action as needed. |
As required. | Monitoring of incidents helps identification of trends and additional information to support the risk assessment process and inform development of education and prevention materials. | Action as required. | |
| F&DA Substances | Substances in F&DA Products: Environmental assessment regulations (EAR) under the F&DA of medicinal ingredients in human and animal drugs that receive a Drug Identification Number (Class 1 substances). Environmental Assessment Regulations under CEPA 1999 for all other new F&DA substances in F&DA products (Class 2 substances). |
As required. | These regulations will replace the New Substance Notification Regulations under CEPA 1999 as they currently apply to new F&DA substances. The EAR will outline data requirements and assessment timelines for industry so that government can conduct risk assessments and, as required, take risk management actions. | EAR for Class 1 substances: Regulations in Canada Gazette, Part I, in 2017; Development of guidance and program requirements in 2017/18; Regulations in Canada Gazette, Part II, in 2018 EAR for Class 2 substances in Canada Gazette, Part I in 2020 and Part II in 2021 |
| Recommendations and/or path forward for where improvements could be made to Non Regulatory Initiatives (NRI) to reduce the release of F&DA substances/products into the environment. | NRI complement regulatory and legislative risk management measures by helping to reduce or mitigate the risk posed by F&DA substances entering the Canadian environment. NRI can achieve this by targeting consumer and industry actions and can help reduce regulatory burden to industry. |
Multi-stakeholder Consultation report available early in FY 2016/17 Based on consultation results a proposed path forward/work plan for NRI will be developed by the end of 2016. 2017-2021: Implementation of work plan objectives which could include support for development and implementation of new or improved NRI for F&DA substances/products, risk management recommendations, education, guidance and research. |
||
| In Commerce List: Assessment of substances on the Revised In Commerce List (ICL) |
Revised ICL contains approximately 3,670 substances. Several hundred are anticipated to be identified for further consideration. | The ICL is a list of substances contained in products that are regulated under the F&DA, but were in Canadian commerce between January 1, 1987 and September 13, 2001. | Complete assessment of those substances identified on the ICL, for further consideration during prioritization, by 2020-2021. | |
| Reassessment: Reassessment of previously assessed substances |
This will include food contaminants, food additives and food packaging materials to ensure they meet current standards. | Ongoing. |
| Regulatory Regime | Planned Government Action | Number of Substances | Rationale for Action | Timelines |
|---|---|---|---|---|
| Canadian Environmental Protection Act, 1999 (CEPA 1999) | Phase 1 and 2 Substances: Complete draft screening assessments of remaining CMP Phase 1 (Challenge Initiative and the Petroleum Sector Stream Approach) and CMP Phase 2 (Groupings Initiative) substances and, as needed, follow-up information gathering or risk management actions. |
Approximately 120 | These substances were identified as priorities under the CMP to be assessed by 2021. The assessments were initiated under phase 1 or 2 of the CMP. | Publication will occur in the early onset of phase 3 of the CMP. For those substances identified for follow-up information gathering actions, measures will be proposed after the final assessment is published. |
| Phase 3 Substances: Conduct risk assessments of remaining priorities, and, as needed, follow-up information gathering or risk management actions. |
Approximately 1,550 List of Substances in the next phase of CMP (2016-2021) |
These substances were identified as priorities under the CMP Plan to be assessed by 2021, or via the review process for the Identification of Risk Assessment Priorities: Results of the 2015 Review. | Assessments will be published as indicated in the two-year rolling risk assessment publication plan. For those substances identified for follow-up information gathering actions, measures will be proposed after the final assessment is published. |
|
| Risk Management (RM) of Toxic Substances: Continuing administration and implementation of over 180 RM instruments and continued development of new instruments. |
Over 600 individual substances represented by 132 listings on Schedule 1 of the CEPA 1999 (List of Toxic Substances) | RM actions, including instruments respecting preventive or control actions (per section 92 of CEPA 1999), are applied to substances concluded as toxic, within the meaning of section 64 of CEPA 1999. Consultation on RM begins when substances are first proposed to be concluded as toxic, and continues throughout the risk management cycle. |
RM actions for toxic substances are to be taken within 3.5 years of the final assessment and statement that the Minister's propose that the substance be added to Schedule 1 of CEPA 1999. RM activities and engagement opportunities will occur on an ongoing basis throughout the RM cycle, and anticipated timelines are provided in the two year rolling risk management activities and consultations schedule. |
|
| Performance measurement: Implement substance based performance measurement (SBPM) for four pilot substances. Develop SBPM plans for additional toxic substances. Conduct effectiveness evaluation for certain CEPA instruments. |
4 plans developed to date Additional substances to be announced |
Performance measurement is used to assess ongoing relevance, success and effectiveness of the actions taken to address the risk, that is, have objectives been met? Substance-based performance measurement is an initiative that considers performance of all instruments, together with relevant data or indicators of exposure to the environment or human health to measure whether environmental and/or human health objectives are being met. |
Ongoing: Information on performance measurement activities is provided in the two year rolling risk management activities and consultations schedule. | |
| Information Gathering Activities: Information gathering activities building on the information submitted by stakeholders via the Domestic Substances List (DSL) Inventory Update in 2012. Access to information via information sharing agreements with domestic and international programs. |
Approximately 1,550 | Updated information on substances in commerce in Canada, volumes and uses is required to support timely risk assessment and risk management decisions. | Information is to be gathered prior to the start of assessment in most cases. Further targeted information gathering may occur after the start of assessment. Information may be gathered to inform risk management actions as required. |
|
| Inventory Update: Inventory Update (IU) on existing substances to determine commercial status |
Approximately 1,500 (TBC after stakeholder consultation) | Updated information on substances in commerce in Canada, volumes and uses is required to inform risk assessment and risk management decisions. | Survey launch planned for 2016 and cyclical every 4 years. | |
| New Substances: Assessment of new substances |
Approximately 500 notifications assessed per year; 30 control measures developed per year. | New Substance Notifications are required for all new substances proposed for introduction into the Canadian marketplace as per the New Substances Notification Regulations under CEPA 1999. | Ongoing. | |
| Products of Biotechnology: Publication of draft and final screening assessments of micro-organisms on the DSL that were assessed during the second phase of the CMP. |
Approximately 16 draft and 21 final publications. | 68 organisms were identified for assessment under section 74 of CEPA 1999, and assessed during CMP Phase 2. | Publication of all final assessments by 2017-18. | |
| DSL Nanomaterials: Prioritisation of substances in commerce according to responses to the section 71 survey. Screening assessment of high priority nanomaterials on the DSL. |
TBD (dependent on results of information gathering initiatives, currently underway) | Prioritization is needed to identify which substances should be assessed for risks to the environment or human health. | Develop and implement Government of Canada approach and guidance for the prioritization of existing nanomaterials, complete prioritisation by 2018. Assessments completed and published as required. |
|
| Monitoring: Ongoing monitoring of chemicals in the environment and humans. |
Varies by monitoring activities and program needs; up to 90 substances measured in human biomonitoring studies. | Monitoring provides essential information used to make sound and effective public health and environmental health policies and interventions, and helps to measure the effectiveness of Government actions to limit or reduce potential risks to humans and/or the environment. | Various ongoing initiatives, including reports on Cycle 4 of the Canadian Health Measures Survey (CHMS) in 2017 and Cycle 5 in 2019, and annual review of environmental monitoring activities based on program priorities. | |
| Research: Research on effects, exposure and methods and tool development. |
Varies by project and program needs. | Research is needed to better understand the exposure and effects of a variety of chemicals that were identified as priorities under the CMP, as well as to develop new tools to efficiently and effectively assess risks. | Complete 3rd cycle of research projects by March 2017 and launch 4th cycle of research projects in 2017-18. Environmental research projects to be conducted from 2016 to 2019. Launch of next cycle of environmental research projects in 2019-2020. |
|
| Compliance and Enforcement | Depending on number of assessed and the resultant risk management outcomes. | Compliance promotion and enforcement activities ensure that regulatees are aware, understand and comply with regulatory requirements. | Ongoing. | |
| Drinking Water: Guidelines for Canadian Drinking Water Quality. |
Approximately 5 per year (new or revised). | These health-based guidelines for existing, new and emerging contaminants that can impact health are developed through a Federal-Provincial-Territorial process. They are used by all jurisdictions in Canada to establish drinking water requirements to protect public health. | Ongoing. | |
| Canada Consumer Product Safety Act (CCPSA) Cosmetic Regulations under the Food and Drugs Act (F&DA) |
Consumer Products and Cosmetics: Continued surveillance of consumer products and cosmetics through analytical testing of levels of substances in these products. |
Levels of substances in these products currently on the market are required to inform risk assessment, and to target appropriate risk management actions. | Ongoing. | |
| Pest Control Products Act (PCPA) | Pesticides: Initiate re-evaluations Re-evaluation of registered pesticides. |
As required. | The PCPA requires a cyclical review (15 years) of all pesticides. | 2016 to 2021, or according to PCPA timelines. |
| Pesticides: re-evaluation of older chemicals. |
46 older active ingredients in 1,817 substances. | The PCPA requires that all pesticides registered prior to 1995 be re-evaluated. | 2016 to 2021, or according to PMRA published work plan. | |
| Pesticides: Initiate special reviews (see Regulatory Directive: Pest Management Regulatory Agency Re-evaluation Program - program 4). |
As required. | Special reviews will be undertaken where there are reasonable grounds that health and environmental risks or value of a pesticide is unacceptable or when a member country of the Organization for Economic Co-operation and Development prohibits all uses of an active ingredient for health or environmental reasons. | Action as required. | |
| Pesticides: Continue to monitor pesticide health and environmental incidents and take action as needed. |
As required. | Monitoring of incidents helps identification of trends and additional information to support the risk assessment process and inform development of education and prevention materials. | Action as required. | |
| F&DA Substances | Substances in F&DA Products: Environmental assessment regulations (EAR) under the F&DA of medicinal ingredients in human and animal drugs that receive a Drug Identification Number (Class 1 substances). Environmental Assessment Regulations under CEPA 1999 for all other new F&DA substances in F&DA products (Class 2 substances). |
As required. | These regulations will replace the New Substance Notification Regulations under CEPA 1999 as they currently apply to new F&DA substances. The EAR will outline data requirements and assessment timelines for industry so that government can conduct risk assessments and, as required, take risk management actions. | EAR for Class 1 substances: Regulations in Canada Gazette, Part I, in 2017; Development of guidance and program requirements in 2017/18; Regulations in Canada Gazette, Part II, in 2018 EAR for Class 2 substances in Canada Gazette, Part I in 2020 and Part II in 2021 |
| Recommendations and/or path forward for where improvements could be made to Non Regulatory Initiatives (NRI) to reduce the release of F&DA substances/products into the environment. | NRI complement regulatory and legislative risk management measures by helping to reduce or mitigate the risk posed by F&DA substances entering the Canadian environment. NRI can achieve this by targeting consumer and industry actions and can help reduce regulatory burden to industry. |
Multi-stakeholder Consultation report available early in FY 2016/17 Based on consultation results a proposed path forward/work plan for NRI will be developed by the end of 2016. 2017-2021: Implementation of work plan objectives which could include support for development and implementation of new or improved NRI for F&DA substances/products, risk management recommendations, education, guidance and research. |
||
| In Commerce List: Assessment of substances on the Revised In Commerce List (ICL) |
Revised ICL contains approximately 3,670 substances. Several hundred are anticipated to be identified for further consideration. | The ICL is a list of substances contained in products that are regulated under the F&DA, but were in Canadian commerce between January 1, 1987 and September 13, 2001. | Complete assessment of those substances identified on the ICL, for further consideration during prioritization, by 2020-2021. | |
| Reassessment: Reassessment of previously assessed substances |
This will include food contaminants, food additives and food packaging materials to ensure they meet current standards. | Ongoing. |
Page details
- Date modified: